Current standard immunotherapy with medications such as keytruda, opdivo or yervoy results vary depending on many factors with a 24 month survival rate of 53% in melanoma, a better responding cancer, with occasional cures. These therapies are expensive, have side effects and still are lacking in results. We now have made a quantum leap in cancer treatment by adding ablation with vaccine adjuvants, completely blowing away the results of standard immunotherapy. https://williamscancerinstitute.com